stockrow
Saturday 7 November 2026
Export BBLG’s income statement to Excel — free account
Bone Biologics Corp.
BBLG Healthcare Biotechnology
- EPS
- +55.3%
- Free cash flow
- +9.99%
Quarter to September 2026, against a year earlier
0.33
0.01
+3.13%
Follow BBLG
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
| (47.49%) | (54.96%) | (75.40%) | (70.17%) |
+8 more TTM periods Free account |
|
| (44.46%) | (50.55%) | (70.20%) | (64.38%) | ||
ROIC |
0.00% | 0.00% | (1,340.96%) | (4,680.27%) | |
Return on Tangible Assets |
(47.75%) | (73.66%) | (61.20%) | (57.81%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.69) | (1.46) | (1.43) | (2.29) | |
Free Cash Flow |
(2.57) | (2.63) | (2.57) | (2.69) | |
| Other line items | |||||
Cash ROIC |
(21.34%) | (33.04%) | (27.93%) | (25.12%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.90 | 0.91 | 0.90 | 0.87 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.69) | (1.46) | (1.43) | (2.29) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 2 Nov 2026